GeneDx Holdings Corp. (WGS)

Company

GeneDx Holdings Corp. (WGS)

SPAC: CM Life Sciences, Inc. (CMLF)

StatusJul 22, 2021
HealthHealth
Merger / DESPACMerger / DESPAC
  1. 0%SPAC/IPOIPOSep 2020
    0%SPAC/IPOIPOSep 2020
  2. 25%LOILOI
    25%LOILOI
  3. 50%AgreementDealFeb 2021
    50%AgreementDealFeb 2021
  4. 75%Merger voteVoteJul 2021
    75%Merger voteVoteJul 2021
  5. 100%MergerMergerJul 2021
    100%MergerMergerJul 2021
5M5M1D

Merger · Jul 2021

SPAC/IPO details
1 unit consists of 1 share + 1/3 Warrant
Prospectus volume (424B4)385 m USD38,500,000 Units · 10 USD/Unit
IPO closed (8-K)442.75 m USD44,275,000 Units · 10 USD/Unit

At GeneDx (Nasdaq: WGS), we believe that everyone deserves personalized, targeted medical care—and that it all begins with a genetic diagnosis. Fueled by one of the world’s largest rare disease data sets, our industry-leading exome and genome tests translate complex genomic data into clinical answers that unlock personalized health plans, accelerate drug discovery, and improve health system efficiencies. For more information, please visit genedx.com and connect with us on LinkedIn, X, Facebook, and Instagram.

Chart/Sentiment

Financials

GeneDx Holdings Corp. (WGS)

Latest quarterly filing: 10-Q
Period endRevenue
2025-12-3110-K
427.5 m USD
2024-12-3110-K
305.5 m USD
2023-12-3110-K
202.6 m USD
2022-12-3110-K
234.7 m USD
2021-12-3110-K
212.2 m USD
2020-12-3110-K
179.3 m USD

Source: SEC Company Facts · USD. Some values may be calculated; please verify them against the official SEC filings.

Scroll to Top